Penn, D., Schmidt-Sommerfeld, E., and Pascu, F
A Trained System A trained body responds differently: It can stay with intensity without collapsing
In 2022, the company that owns the patent of Eriomin funded a small trial involving 45 people, concluding that those who took it over a 12-week period had lower blood glucose and higher GLP-1 than those who took a placebo
"New trends are going to come along, new medications are going to come along, but if we don't address the underlying cultural attitudes to certain bodies, we're never going to address the real issue." Addressing these issues, she added, could be a matter of "everyday practices"
We have no clue how you'll respond or whether it's safe." To lose a small amount of weight Influencers often tout microdosing as a way to lose "those last 10 pounds," despite the fact that GLP-1 drugs are approved for people with obesity or those who are overweight and have related health conditions